Survival and morbidity outcomes after pelvic exenteration for pelvic sarcoma: an institutional series.
Peter J LeeBabak MeshkatPrashanth SasidharanAssad ZahidDavid J CokerMichael J SolomonPublished in: ANZ journal of surgery (2021)
In our cohort of patients with locally advanced and recurrent disease, more than 50% achieved an R0 resection. Recurrent disease makes R0 resection more difficult and can lead to higher morbidity, need for 30-day re-intervention and longer in hospital LOS. PE surgery remains the only curative option for locally advanced, and recurrent sarcoma in the pelvis, and can be performed with acceptable survival and morbidity outcomes.
Keyphrases
- rectal cancer
- locally advanced
- randomized controlled trial
- minimally invasive
- squamous cell carcinoma
- neoadjuvant chemotherapy
- healthcare
- free survival
- radiation therapy
- type diabetes
- coronary artery bypass
- coronary artery disease
- insulin resistance
- prognostic factors
- surgical site infection
- electronic health record
- open label